Retinopathy of prematurity and antenatal corticosteroids

V. Console, L. Gagliardi, A. De Giorgi, E. De Ponti, G. Di Stefano, M. G. Romeo, A. Senderi, M. DiPietro, F. Pisano, S. Silvano, M. Anghileri, R. Zanini, E. Lanza, N. Pellizzari, A. M. Raimondi, M. L. Brambilla, M. T. Marsili, D. Rosti, M. E. Bettinelli, S. AccertaD. Spinelli, C. Borroni, L. Abbiari, C. Carlevaro, E. Bertazzi, P. Zaramella, S. Perrone, M. A. Didato, A. Gioeli, G. Cascio, M. Scimeni, E. Volante, L. Gambini, F. Neri, A. Maserati, G. Chinco, C. Migliori, P. E. Bianchi, R. Guagliano, C. Romagnoli, F. Gallini, G. Mintcucci, R. Ricci, G. Guala, L. Fogli, G. Anselmetti, M. R. Berti, D. Pedrotti, E. Zampedri, S. De Silva, M. C. Fertz, P. Perissutti

Research output: Contribution to journalArticle

Abstract

Objectives. It is not known whether antenatal corticosteroids (ANS) can reduce the risk of retinopathy of prematurity (ROP). The aim of this study was to evaluate in a prospective cohort study the effect of ANS on ROP development and severity. Methods. All infants consecutively admitted to 14 centres from 1.1.1992 to 31.12.1993, with a gestational age ≤ 30 weeks, no congenital anomalies, and who survived to 6 months, were enrolled (N=380). Mean birth weight of the cohort was 1157 g; mean gestational age was 28.4 weeks. ROP stage 1-2 developed in 82 neonates; ROP stage 3-3+ in 57. Only 70 neonates (18.4%) received ANS prophylaxis. Results. ANS prophylaxis highly significantly reduced the risk of developing ROP [Odds ratio, (OR), 0.35; 95% confidence interval 0.17-0.71, logistic regression analysis], and that of severe (stage 3-3+) ROP (OR 0.07; 95% confidence interval; 0.02-0.34). Short gestation, low birth weight, bronchopulmonary dysplasia also were significantly associated with ROP development and severity; respiratory distress syndrome and not being treated with surfactant were significant risk factors for ROP severity. Conclusions. ANS prophylaxis protected both against ROP development and against severe forms of ROP. Prematurity and respiratory morbidity still represent independent risk factors for ROP.

Original languageEnglish
Pages (from-to)75-79
Number of pages5
JournalActa Biomedica
Volume68
Issue numberSUPPL. 1
Publication statusPublished - 1997

Fingerprint

Retinopathy of Prematurity
Adrenal Cortex Hormones
Gestational Age
Odds Ratio
Newborn Infant
Confidence Intervals
Cohort Effect
Bronchopulmonary Dysplasia
Low Birth Weight Infant
Birth Weight
Surface-Active Agents
Cohort Studies
Logistic Models
Regression Analysis
Prospective Studies

Keywords

  • Newborn infant
  • Prophylaxis
  • Retinopathy of prematurity
  • Steroids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Console, V., Gagliardi, L., De Giorgi, A., De Ponti, E., Di Stefano, G., Romeo, M. G., ... Perissutti, P. (1997). Retinopathy of prematurity and antenatal corticosteroids. Acta Biomedica, 68(SUPPL. 1), 75-79.

Retinopathy of prematurity and antenatal corticosteroids. / Console, V.; Gagliardi, L.; De Giorgi, A.; De Ponti, E.; Di Stefano, G.; Romeo, M. G.; Senderi, A.; DiPietro, M.; Pisano, F.; Silvano, S.; Anghileri, M.; Zanini, R.; Lanza, E.; Pellizzari, N.; Raimondi, A. M.; Brambilla, M. L.; Marsili, M. T.; Rosti, D.; Bettinelli, M. E.; Accerta, S.; Spinelli, D.; Borroni, C.; Abbiari, L.; Carlevaro, C.; Bertazzi, E.; Zaramella, P.; Perrone, S.; Didato, M. A.; Gioeli, A.; Cascio, G.; Scimeni, M.; Volante, E.; Gambini, L.; Neri, F.; Maserati, A.; Chinco, G.; Migliori, C.; Bianchi, P. E.; Guagliano, R.; Romagnoli, C.; Gallini, F.; Mintcucci, G.; Ricci, R.; Guala, G.; Fogli, L.; Anselmetti, G.; Berti, M. R.; Pedrotti, D.; Zampedri, E.; De Silva, S.; Fertz, M. C.; Perissutti, P.

In: Acta Biomedica, Vol. 68, No. SUPPL. 1, 1997, p. 75-79.

Research output: Contribution to journalArticle

Console, V, Gagliardi, L, De Giorgi, A, De Ponti, E, Di Stefano, G, Romeo, MG, Senderi, A, DiPietro, M, Pisano, F, Silvano, S, Anghileri, M, Zanini, R, Lanza, E, Pellizzari, N, Raimondi, AM, Brambilla, ML, Marsili, MT, Rosti, D, Bettinelli, ME, Accerta, S, Spinelli, D, Borroni, C, Abbiari, L, Carlevaro, C, Bertazzi, E, Zaramella, P, Perrone, S, Didato, MA, Gioeli, A, Cascio, G, Scimeni, M, Volante, E, Gambini, L, Neri, F, Maserati, A, Chinco, G, Migliori, C, Bianchi, PE, Guagliano, R, Romagnoli, C, Gallini, F, Mintcucci, G, Ricci, R, Guala, G, Fogli, L, Anselmetti, G, Berti, MR, Pedrotti, D, Zampedri, E, De Silva, S, Fertz, MC & Perissutti, P 1997, 'Retinopathy of prematurity and antenatal corticosteroids', Acta Biomedica, vol. 68, no. SUPPL. 1, pp. 75-79.
Console V, Gagliardi L, De Giorgi A, De Ponti E, Di Stefano G, Romeo MG et al. Retinopathy of prematurity and antenatal corticosteroids. Acta Biomedica. 1997;68(SUPPL. 1):75-79.
Console, V. ; Gagliardi, L. ; De Giorgi, A. ; De Ponti, E. ; Di Stefano, G. ; Romeo, M. G. ; Senderi, A. ; DiPietro, M. ; Pisano, F. ; Silvano, S. ; Anghileri, M. ; Zanini, R. ; Lanza, E. ; Pellizzari, N. ; Raimondi, A. M. ; Brambilla, M. L. ; Marsili, M. T. ; Rosti, D. ; Bettinelli, M. E. ; Accerta, S. ; Spinelli, D. ; Borroni, C. ; Abbiari, L. ; Carlevaro, C. ; Bertazzi, E. ; Zaramella, P. ; Perrone, S. ; Didato, M. A. ; Gioeli, A. ; Cascio, G. ; Scimeni, M. ; Volante, E. ; Gambini, L. ; Neri, F. ; Maserati, A. ; Chinco, G. ; Migliori, C. ; Bianchi, P. E. ; Guagliano, R. ; Romagnoli, C. ; Gallini, F. ; Mintcucci, G. ; Ricci, R. ; Guala, G. ; Fogli, L. ; Anselmetti, G. ; Berti, M. R. ; Pedrotti, D. ; Zampedri, E. ; De Silva, S. ; Fertz, M. C. ; Perissutti, P. / Retinopathy of prematurity and antenatal corticosteroids. In: Acta Biomedica. 1997 ; Vol. 68, No. SUPPL. 1. pp. 75-79.
@article{6318a228cbd34a9782d7be1583675e17,
title = "Retinopathy of prematurity and antenatal corticosteroids",
abstract = "Objectives. It is not known whether antenatal corticosteroids (ANS) can reduce the risk of retinopathy of prematurity (ROP). The aim of this study was to evaluate in a prospective cohort study the effect of ANS on ROP development and severity. Methods. All infants consecutively admitted to 14 centres from 1.1.1992 to 31.12.1993, with a gestational age ≤ 30 weeks, no congenital anomalies, and who survived to 6 months, were enrolled (N=380). Mean birth weight of the cohort was 1157 g; mean gestational age was 28.4 weeks. ROP stage 1-2 developed in 82 neonates; ROP stage 3-3+ in 57. Only 70 neonates (18.4{\%}) received ANS prophylaxis. Results. ANS prophylaxis highly significantly reduced the risk of developing ROP [Odds ratio, (OR), 0.35; 95{\%} confidence interval 0.17-0.71, logistic regression analysis], and that of severe (stage 3-3+) ROP (OR 0.07; 95{\%} confidence interval; 0.02-0.34). Short gestation, low birth weight, bronchopulmonary dysplasia also were significantly associated with ROP development and severity; respiratory distress syndrome and not being treated with surfactant were significant risk factors for ROP severity. Conclusions. ANS prophylaxis protected both against ROP development and against severe forms of ROP. Prematurity and respiratory morbidity still represent independent risk factors for ROP.",
keywords = "Newborn infant, Prophylaxis, Retinopathy of prematurity, Steroids",
author = "V. Console and L. Gagliardi and {De Giorgi}, A. and {De Ponti}, E. and {Di Stefano}, G. and Romeo, {M. G.} and A. Senderi and M. DiPietro and F. Pisano and S. Silvano and M. Anghileri and R. Zanini and E. Lanza and N. Pellizzari and Raimondi, {A. M.} and Brambilla, {M. L.} and Marsili, {M. T.} and D. Rosti and Bettinelli, {M. E.} and S. Accerta and D. Spinelli and C. Borroni and L. Abbiari and C. Carlevaro and E. Bertazzi and P. Zaramella and S. Perrone and Didato, {M. A.} and A. Gioeli and G. Cascio and M. Scimeni and E. Volante and L. Gambini and F. Neri and A. Maserati and G. Chinco and C. Migliori and Bianchi, {P. E.} and R. Guagliano and C. Romagnoli and F. Gallini and G. Mintcucci and R. Ricci and G. Guala and L. Fogli and G. Anselmetti and Berti, {M. R.} and D. Pedrotti and E. Zampedri and {De Silva}, S. and Fertz, {M. C.} and P. Perissutti",
year = "1997",
language = "English",
volume = "68",
pages = "75--79",
journal = "Acta Biomedica de l'Ateneo Parmense",
issn = "0392-4203",
publisher = "L'Ateneo Parmense",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Retinopathy of prematurity and antenatal corticosteroids

AU - Console, V.

AU - Gagliardi, L.

AU - De Giorgi, A.

AU - De Ponti, E.

AU - Di Stefano, G.

AU - Romeo, M. G.

AU - Senderi, A.

AU - DiPietro, M.

AU - Pisano, F.

AU - Silvano, S.

AU - Anghileri, M.

AU - Zanini, R.

AU - Lanza, E.

AU - Pellizzari, N.

AU - Raimondi, A. M.

AU - Brambilla, M. L.

AU - Marsili, M. T.

AU - Rosti, D.

AU - Bettinelli, M. E.

AU - Accerta, S.

AU - Spinelli, D.

AU - Borroni, C.

AU - Abbiari, L.

AU - Carlevaro, C.

AU - Bertazzi, E.

AU - Zaramella, P.

AU - Perrone, S.

AU - Didato, M. A.

AU - Gioeli, A.

AU - Cascio, G.

AU - Scimeni, M.

AU - Volante, E.

AU - Gambini, L.

AU - Neri, F.

AU - Maserati, A.

AU - Chinco, G.

AU - Migliori, C.

AU - Bianchi, P. E.

AU - Guagliano, R.

AU - Romagnoli, C.

AU - Gallini, F.

AU - Mintcucci, G.

AU - Ricci, R.

AU - Guala, G.

AU - Fogli, L.

AU - Anselmetti, G.

AU - Berti, M. R.

AU - Pedrotti, D.

AU - Zampedri, E.

AU - De Silva, S.

AU - Fertz, M. C.

AU - Perissutti, P.

PY - 1997

Y1 - 1997

N2 - Objectives. It is not known whether antenatal corticosteroids (ANS) can reduce the risk of retinopathy of prematurity (ROP). The aim of this study was to evaluate in a prospective cohort study the effect of ANS on ROP development and severity. Methods. All infants consecutively admitted to 14 centres from 1.1.1992 to 31.12.1993, with a gestational age ≤ 30 weeks, no congenital anomalies, and who survived to 6 months, were enrolled (N=380). Mean birth weight of the cohort was 1157 g; mean gestational age was 28.4 weeks. ROP stage 1-2 developed in 82 neonates; ROP stage 3-3+ in 57. Only 70 neonates (18.4%) received ANS prophylaxis. Results. ANS prophylaxis highly significantly reduced the risk of developing ROP [Odds ratio, (OR), 0.35; 95% confidence interval 0.17-0.71, logistic regression analysis], and that of severe (stage 3-3+) ROP (OR 0.07; 95% confidence interval; 0.02-0.34). Short gestation, low birth weight, bronchopulmonary dysplasia also were significantly associated with ROP development and severity; respiratory distress syndrome and not being treated with surfactant were significant risk factors for ROP severity. Conclusions. ANS prophylaxis protected both against ROP development and against severe forms of ROP. Prematurity and respiratory morbidity still represent independent risk factors for ROP.

AB - Objectives. It is not known whether antenatal corticosteroids (ANS) can reduce the risk of retinopathy of prematurity (ROP). The aim of this study was to evaluate in a prospective cohort study the effect of ANS on ROP development and severity. Methods. All infants consecutively admitted to 14 centres from 1.1.1992 to 31.12.1993, with a gestational age ≤ 30 weeks, no congenital anomalies, and who survived to 6 months, were enrolled (N=380). Mean birth weight of the cohort was 1157 g; mean gestational age was 28.4 weeks. ROP stage 1-2 developed in 82 neonates; ROP stage 3-3+ in 57. Only 70 neonates (18.4%) received ANS prophylaxis. Results. ANS prophylaxis highly significantly reduced the risk of developing ROP [Odds ratio, (OR), 0.35; 95% confidence interval 0.17-0.71, logistic regression analysis], and that of severe (stage 3-3+) ROP (OR 0.07; 95% confidence interval; 0.02-0.34). Short gestation, low birth weight, bronchopulmonary dysplasia also were significantly associated with ROP development and severity; respiratory distress syndrome and not being treated with surfactant were significant risk factors for ROP severity. Conclusions. ANS prophylaxis protected both against ROP development and against severe forms of ROP. Prematurity and respiratory morbidity still represent independent risk factors for ROP.

KW - Newborn infant

KW - Prophylaxis

KW - Retinopathy of prematurity

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=7344243177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7344243177&partnerID=8YFLogxK

M3 - Article

C2 - 10021720

AN - SCOPUS:7344243177

VL - 68

SP - 75

EP - 79

JO - Acta Biomedica de l'Ateneo Parmense

JF - Acta Biomedica de l'Ateneo Parmense

SN - 0392-4203

IS - SUPPL. 1

ER -